Maravai LifeSciences (MRVI) announced its acquisition of intellectual property and relevant assets from Molecular Assemblies, or MAI. The acquisition will expand Maravai and TriLink BioTechnologies’ ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai LifeSciences Restructures Leadership Amid Revenue Update
- Maravai sees 2024 revenue at midpoint of $255M-$265M range
- Maravai Lifesciences initiated with a Neutral at Guggenheim
- Maravai Lifesciences chairman Carl Hull to retire, R. Andrew Eckert to succeed
- Maravai LifeSciences Appoints New Chairman Amid Leadership Transition